- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
When treatment decisions depend on molecular results, turnaround time matters. In oncology, delays in receiving Next-Generation Sequencing (NGS) results can add stress for patients and slow critical decisions for physicians, which is why a faster and more reliable testing timeline is an important part of quality cancer care.
Cancer care often moves quickly, and physicians may need molecular information as soon as possible to support treatment planning. A shorter turnaround time helps reduce delays between specimen submission, result delivery, and next-step clinical decisions.
The current GTC page highlights the emotional burden created by delayed results, noting that patients who wait longer for treatment experience significant anxiety and stress. Faster NGS testing timelines can improve the overall experience for both patients and care teams.
Next-gen sequencing testing is more complex than traditional methods such as FISH, flow cytometry, IHC, and cytogenetics, but complexity should not mean unnecessary delay. Physicians and patients still need results within a clinically useful timeframe.
GTC positions its turnaround time as a point of differentiation by stating that it offers this complex molecular profiling for cancer in 5–10 days. That faster delivery model helps align comprehensive genomic testing with the time-sensitive realities of oncology care.
Genomic Testing Cooperative (GTC) is using disruptive technology and will report results within 5-10 days of receiving the sample. GTC tests all exons of >400 DNA genes for solid tumors and >300 RNA genes for hematology and liquid biopsies. Provides a comprehensive report within 5-10 days from receiving a sample at our lab.
Despite this extensive testing and comprehensive reporting, GTC is committed to offeingr these panels at an affordable price. For more information, visit our test menu
Turnaround time matters because cancer treatment decisions often depend on timely diagnostic and molecular information. When results take too long, patients may experience added uncertainty and stress, while physicians may face delays in treatment planning.
NGS testing is a more complex methodology than many traditional diagnostic approaches. The current GTC page specifically contrasts next-gen sequencing with methods such as FISH, flow cytometry, IHC, and cytogenetics, indicating that broader molecular profiling generally requires a more complex workflow.
Yes. While comprehensive profiling is inherently complex, the value proposition presented by GTC is that advanced molecular testing can still be delivered within a clinically meaningful timeframe. The page specifically states that GTC offers this complex profiling in 5–10 days
A useful turnaround time is one that supports timely clinical decisions without compromising the value of comprehensive testing. GTC frames its offering around a 5–10 day window, positioning that timeline as a way to meet the need for both breadth and speed in oncology testing.
For physicians, faster turnaround time can mean earlier access to molecular findings, fewer delays in decision-making, and a more efficient path from specimen submission to treatment planning. In time-sensitive oncology settings, this can improve the usability of NGS testing in real clinical workflows.
For patients, shorter wait times may reduce some of the anxiety and stress associated with delayed answers and delayed treatment. The current GTC page explicitly connects longer waits with emotional burden, which makes timeliness an important part of the patient experience as well as the clinical process.
Comprehensive genomic profiling is most valuable when it reaches physicians in time to support meaningful clinical action. By combining broad molecular testing with a turnaround time designed for real-world oncology care, GTC presents a model in which NGS testing can be both comprehensive and timely.
Learn how GTC’s genomic testing solutions use Next-Generation Sequencing (NGS) to support comprehensive molecular profiling across solid tumors, hematologic malignancies, and liquid biopsy applications.
